Kane Biotech Inc.
KNE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.20% | -31.02% | 11.04% | -75.07% | 70.33% |
| Total Depreciation and Amortization | -32.85% | -40.95% | -11.79% | -21.49% | 0.60% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 160.83% | 359.46% | -215.63% | 117.66% | -164.48% |
| Change in Net Operating Assets | -94.19% | 202.58% | 7.11% | 56.61% | -165.81% |
| Cash from Operations | -27.89% | 28.47% | 3.69% | 9.26% | 27.36% |
| Capital Expenditure | -- | -- | -- | -100.00% | 166.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -144.09% | 40.76% | -282.93% | 88.58% | -65.44% |
| Cash from Investing | -144.09% | 40.76% | -139.75% | 233.90% | 5.45% |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | 100.00% | 66.29% | 18.22% | 81.10% | 26.83% |
| Issuance of Common Stock | -- | -- | -- | -100.00% | -25.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -110.63% | 337.93% | 78.25% | -210.08% |
| Cash from Financing | 13,772.41% | -101.22% | 2,278.54% | -101.57% | 56.25% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 188.86% | -1,259.33% | 94.52% | -160.47% | 761.66% |